The Efficacy of Goal-Directed Valsalva to Elicit Clinically Significant Gradients in Patients With Obstructive Hypertrophic Cardiomyopathy Taking Mavacamten Therapy

J Am Soc Echocardiogr. 2024 Oct 12:S0894-7317(24)00504-2. doi: 10.1016/j.echo.2024.10.002. Online ahead of print.

Authors

Cody Frye¹, Melissa Escudero², William Saunders², Olafunke Ajijola², George Mawardi², Shuktika Nandkeolyar², Noreen Kelly², Dermot Phelan²

Affiliations

¹ Atrium Health, Sanger Heart & Vascular Institute, Hypertrophic Cardiomyopathy Center, Charlotte, North Carolina. Electronic address: cody.frye@atriumhealth.org.
² Atrium Health, Sanger Heart & Vascular Institute, Hypertrophic Cardiomyopathy Center, Charlotte, North Carolina.

PMID: 39401730
DOI: 10.1016/j.echo.2024.10.002

No abstract available

Publication types

Letter